This level of immunity is particularly important for individuals with compromised immune systems and those who do not respond to vaccines.
According to CNBC, the American pharmaceutical company Regeneron Pharmaceuticals has reported that a single dose of their antibody can reduce the risk of contracting Covid-19 by 81.6% within a period of 2 to 8 months after administration. Currently, this Covid-19 antibody treatment named REGEN-COV is in its final testing phase.
A vial of REGEN-COV monoclonal antibody placed on a medical table at the Emergency Care Center in Sarasota, Florida, USA on September 23. (Photo: Reuters).
Myron Cohen, head of monoclonal antibody studies for the Covid Prevention Network funded by the U.S. National Institutes of Health, stated that trial results indicate the REGEN-COV antibody therapy has the potential to provide long-lasting immunity against the infectious disease Covid-19.
Meanwhile, Regeneron Pharmaceuticals emphasized that such immunity is especially crucial for individuals with weakened immune systems and those who do not respond to vaccines.
This therapy previously showed a reduction of 81.4% in the risk of contracting Covid-19 during the first month after administration.
Throughout the 8-month evaluation period, there were no hospitalizations due to Covid-19 among the group receiving REGEN-COV.
In July, the U.S. health authorities expanded the authorization of REGEN-COV to allow its use as a preventive treatment for individuals exposed to Covid-19 patients, as well as for those at high risk of exposure in facilities such as nursing homes or prisons.
